An interventional study of Methadone 0.15 mg/kg and morphine in Cesarean Section Pain, sponsored by Clinica Alemana de Santiago. Not yet recruiting. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Clinica Alemana de Santiago · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing methadone in Pain — 3 open to participants now, 3 under way, none of them phase 3. Methadone · Pain.
Among the 29 studies testing methadone in Pain, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 6 with no phase, and was the 29th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →3 of the 29 studies testing methadone in Pain are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 6 mo–4 yrs
University of Virginia · Sites in United States
Ages 18–65
By country, each count listing its studies:
Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 3 · Phase 4 6
First in 1996; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 40 across the 29 interventional studies. Of the 24 that completed or were terminated, 9 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 29 have an industry lead sponsor. The 10 most frequent:
Clinica Alemana de Santiago is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Clinica Alemana de Santiago has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
3 of the studies testing methadone in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07777029Clinica Alemana de SantiagoSubcutaneous Methadone for Cesarean Analgesia: a Non Inferiority Study Using QoR-10 | 2026-12-31 |
| NCT06962306Duke UniversityOptimizing Perioperative Analgesia to Lower Pain Following Cleft Palate Surgery | 2027-06-04 |
| NCT06810336University of VirginiaPain Control and Quality of Recovery After Intravenous Methadone Versus Intravenous Remifentanil in Craniotomy Surgery | 2027-09-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies testing methadone in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate whether subcutaneous methadone provides postoperative analgesia that is non-inferior to that achieved with intrathecal morphine in women undergoing cesarean delivery under neuraxial anesthesia. The primary outcome will be the quality of postoperative recovery, assessed using the QoR-10 score during the first 24 hours after surgery. Secondary outcomes will include postoperative pain intensity, opioid consumption, incidence of adverse effects, and maternal satisfaction.
This trial seeks to determine whether subcutaneous methadone could represent an alternative analgesic strategy within multimodal analgesia protocols for cesarean delivery.
Effective postoperative analgesia following cesarean delivery is a fundamental component of maternal recovery and patient satisfaction. Current international recommendations, including the most recent 2026 update from the PROSPECT Working Group, emphasize that neuraxial morphine remains the gold standard for postoperative analgesia. These guidelines also highlight the strong evidence supporting multimodal analgesia strategies, including the routine use of paracetamol and dexamethasone as adjuncts to improve analgesic outcomes and postoperative recovery.
Despite its efficacy, intrathecal morphine may be associated with dose-dependent adverse effects, such as pruritus, nausea, vomiting, and respiratory depression. For this reason, there remains ongoing clinical interest in identifying alternative analgesic strategies that provide comparable efficacy with a more favorable safety profile.
Methadone is a long-acting opioid that also exhibits N-methyl-D-aspartate (NMDA) receptor antagonist properties, which may enhance analgesia and reduce postoperative opioid requirements. There is evidence supporting its use in cesarean delivery when administered intravenously. In particular, a randomized trial demonstrated that intravenous methadone provides effective postoperative analgesia following cesarean delivery. However, other routes of administration have not been adequately evaluated in this setting.
The subcutaneous route may offer several potential advantages, including ease of administration, predictable absorption, and sustained systemic drug exposure, which could make it a practical alternative in obstetric analgesia. To date, subcutaneous methadone has not been evaluated nor directly compared with intrathecal morphine, which remains the current standard for post-cesarean analgesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive subcutaneous methadone for postoperative analgesia following cesarean delivery under neuraxial anesthesia as part of a multimodal analgesia regimen.
Drug: Methadone 0.15 mg/kg
Patients recieve intrathecal preservative-free morphine for postoperative analgesia following cesarean delivery under neuraxial anesthesia as part of a multimodal analgesia regimen.
Drug: morphine
Quality of Recovery-10 (QoR-10) score at 24 hours
cesarean delivery. The QoR-10 is a validated patient-reported outcome measure ranging from 0 to 100, with higher scores indicating better recovery. The study is designed to assess noninferiority of subcutaneous methadone compared to intrathecal morphine using a predefined noninferiority margin of 8 points.
Time frame: 24 hours
Postoperative pain intensity
Pain intensity measured using a numerical rating scale (0-10) at rest and during movement.
Time frame: Up to 24 hours after surgery
Opioid consumption
Total opioid consumtion within the first 24 hours after cesarean section, converted to morphine oral equivalents
Time frame: Up to 24 hours after surgery
adverse effects
incidence of nausea, vomiting, pruritus, somnolence, respiratory deppresion within 24 hours
Time frame: 24 hours
No study locations are listed for this record.
Plan to share: No — No individual participant data will be shared. The raw data will not be publicly available due to participant privacy and ethical constraints.
Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.
Of 3,740 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 4 months is below that.
Counting every sponsor, half of 3,839 studies reached it within 10 months; a quarter within 4 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methadone
Clinica Alemana de Santiago